摘要目的 研究阿格列汀治疗2型糖尿病合并冠心病患者的临床效果。方法 选取2017年1月～2018年11月赣州市立医院内分泌老年病科收治的80例2型糖尿病合并冠心病患者作为研究对象，采用电脑随机法将其分为两组，每组各40例。观察组患者采用阿格列汀治疗，对照组患者采用常规治疗。比较两组患者的治疗效果、不良反应发生情况、治疗前后血糖水平、心绞痛每周发作次数以及每次持续时间。结果 观察组患者的治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。观察组患者的不良反应总发生率低于对照组，差异有统计学意义（P＜0.05）。治疗后，观察组患者的空腹血糖（FPG）、餐后2 h 血糖（2 h PG）、糖化血红蛋白（HbA1c）水平均低于对照组，差异有统计学意义（P＜0.05）。治疗后，观察组患者的心绞痛发作次数少于对照组，每次持续时间短于对照组，差异有统计学意义（P＜0.05）。结论 阿格列汀对2型糖尿病合并冠心病患者的疗效较好，能稳定血糖水平，同时能够保障用药安全性，值得研究。
Abstract：Objective To study the clinical effect of Alogliptin in the treatment of patients with type 2 diabetes mellitus complicated with coronary heart disease.Methods A total of 80 patients with type 2 diabetes mellitus complicated with coronary heart disease from January 2017 to November 2018 in Department of Endocrinology and Geriatrics of Ganzhou Municipal Hospital were selected as the study subjects, and divided into two groups by computer random method,40 cases in each group.The patients in the observation group were treated with Alogliptin, while those in the control group were treated with routine therapy.The treatment effect, adverse reactions, blood glucose levels before and after treatment, number of angina attacks per week and duration of each angina attack were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group, with statistically significant differences (P＜0.05).After treatment, the levels of fasting blood glucose (FPG), postprandial blood glucose (2 h PG) and glycosylated hemoglobin (HbA1c) in the observation group were lower than those in the control group, with statistically significant differences (P＜0.05).After treatment, the number of angina attacks in the observation group was less than that in the control group, and the duration of each angina attack was shorter than that in the control group, with statistically significant differences (P＜0.05).Conclusion Alogliptin has a good curative effect on patients with type 2 diabetes complicated with coronary heart disease, which can stabilize blood glucose level and guarantee drug safety.It is worth studying.
Kusamori K，Nishikawa M，Mizuno N，et al.Transplantation of insulin-secreting multicellular spheroids for the treatment of type 1 diabetes in mice[J].J Control Release，2014，173：119-124.
[16]
Colmegna P，Sánchez Pena RS.Analysis of three T1DM simulation models for evaluating robust closed-loop controllers[J].Comput Method Program Biomed，2014，113（1）：371-382.
[17]
Lo J，Ljubicic S，Leibiger B，et al.Adipsin is an Adipokine that improves β cell function in diabetes[J].Cell，2014，158（1）：41-53.
[18]
Skrivarhaug T，Stene LC，Drivvoll AK，et al.Incidence of type 1 diabetes in Norway among children aged 0-14 years between 1989 and 2012：Has the incidence stopped rising results from the norwegian childhood diabetes registry[J].Diabetologia，2014，57（1）：57-62.
Holden SE，Bannister CA，Currie CJ.Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment：(questionable) classification of diabetic patients based on combination of specific glucoselowering drugs[J].Diabetologia，2014，57（9）：2001-2002.
京公网安备 11010502046607号